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The purpose of the present study was to determine the effect of metacognitive therapy (MCT) on
symptoms of body dysmorphic disorder (BDD) and on symptoms of thought-fusion, by means of a wait-
list controlled clinical trial. Participants were referred from dermatology and cosmetic surgery clinics in
the city of Isfahan, Iran, and 20 patients were selected on the basis of DSM-IV-TR diagnostic criteria for
BDD. They were randomly assigned to either the experimental or the wait-list control group. The Yale-
Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS) and the
Thought-Fusion Inventory (TFI) were used as the outcome measures. The experimental group received 8
weekly metacognitive intervention sessions. The control group was in the waiting-list until the end of
the follow-up. Measures were taken at pre-test, post-test (after 2 months) and follow-up (after 6-
months). The results of analysis of variance showed that MCT significantly reduced the symptoms of BDD
and of thought-fusion, compared to the wait-list. Effects on both outcome measures were maintained at
6-months follow-up.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
Body dysmorphic disorder (BDD; previously called dysmor-
phophobia) is characterized by a preoccupation with an imagined
defect in one’s appearance or an exaggeration of a slight physical
anomaly (American Psychiatric Association, 2000). The largest
epidemiological study to date (Rief, Buhlmann, Wilhelm,
Borkenhagen, & Brähler, 2006) reported a BDD prevalence rate of
1.7% (95% CI ¼ 1.2%e2.1%) in the community. Prevalence rates are
significantly higher when examined in psychiatric populations
(e.g., 13%e16%; Conroy et al., 2008; Grant, Kim, & Crow, 2001). A
recent Dutch study found 3e8% of the patients in dermatology and
plastic surgery clinics of an academic hospital to be suffering from
BDD (Vulink et al., 2006).
Surveys of BDD patients attending a psychiatric clinic tend to
show an equal sex incidence and sufferers are usually single or
separated (Neziroglu & Yaryura-Tobias, 1993; Phillips & Diaz, 1997).
BDD shares several common characteristics with OCD, such as
similar age of onset, sex ratio, severity of symptoms, persistency,þ31 43 3884196.
l (S. Mulkens).
All rights reserved.and high comorbidity with depression and anxiety disorders
(Phillips, 2009).
Psychological and pharmacological treatments for BDD have
received increasing attention in the past 10 years. Although
psychological and pharmacological treatment approaches for BDD
have been evaluated, only two RCTs were conducted on CBT and
one onmedication for BDD in adults. In one study Rosen, Reiter, and
Orosan (1995) randomly assigned 54 patients to either group CBTor
a no treatment control condition. Groups consisted of four to five
patients who attended 8 weekly 2-h CBT sessions. CBT was signif-
icantly more effective than no treatment: clinically significant
improvement occurred in 82% of the CBTgroupmembers at the end
of treatment, and in 77% at follow-up 4.5 months later. This study
included only females and they were relatively less handicapped
than the patients described in other treatment studies. Their
concerns were mostly about weight and shape, whereas there was
no diagnoseable eating disorder. In the other RCT, Veale et al.
(1996), randomly assigned 19 patients to either CBT or a no treat-
ment control condition. Patients attended to 12 weekly individual
1-h sessions. In the CBT condition, 78% had either no BDD anymore
or BDD symptoms in the subclinical range after treatment, whereas
all 10 waiting-list patients were still in the clinical range of BDD
scores at the end of the trial. In an RCT on medication, Phillips,
Albertini, and Rasmussen (2002) randomly assigned 67
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was superior to placebo. To summarize, evidence of CBT as
a favorable treatment for BDD is still scarce and no RCT has directly
compared CBT to medication yet.
The present study aims to add knowledge to treatment effec-
tiveness for BDD by conducting an RCT comparing Metacognitive
Therapy (MCT; Wells, 2009) with a no treatment control group.
Metacognition refers to knowledge or beliefs about thinking and
strategies used to regulate and control thinking processes (Moses &
Baird, 1998). MCT is based on the idea that metacognitions cause
a particular pattern of responding to inner experiences such as
worry and rumination that maintains negative emotions and
strengthens negative thought. In MCT not the content (per se) of
cognitions (e.g., negative, irrational cognitions about the self (and
appearance), the world, and other people) is addressed - as is done
in cognitive therapy- but merely beliefs about thinking (meta-
cognitive beliefs) and the process itself are the focus of treatment.
In other words, CT attempts to modify the content of perseverative
thinking, i.e., appraisals, rather than the metacognitive processes
which perpetuate the continued maladaptive processing. With
respect to content, certain thoughts (eg., about their appearance)
and intrusions (urges, images and emotions) are referred to. By the
process, the factors that maintain these kinds of intrusions are
referred to. For example, the type of attention (eg., self-focused
attention) may influence thinking style in such a way that infor-
mation which comes in through internal feelings and thoughts is
especially paid attention to and may increase rumination and
worry. This does not mean that BDD patients do not make
appraisals of inflated responsibility or overestimate threat but that
these occur in the stream of rumination/worry. It follows that
modifying the processes and metacognitions that give rise to the
stream of worry could be a more effective treatment approach than
just focusing on the actual content of thoughts. Evidence of the
relationships between metacognitions and OCD symptoms has
been demonstrated using non-patient samples (Fisher & Wells,
2008; Myers & Wells, 2005; Wells, Gwilliam, & Cartwright-
Hatton, 2001), both in experimental studies (Fisher & Wells,
2005a), and patient group comparisons (Janeck, Calamari,
Riemann, & Heffelfinger, 2003).
The metacognitive model of OCD (Wells, 1997) is based on the
more generic model, the Self-Regulatory Executive Function Model
(S-REF) and proposes that intrusive thoughts activate meta-
cognitive knowledge which in turn guides maladaptive processing.
In other words, specific metacognitive beliefs lead to the cognitive
attentional syndrome (CAS). The metacognitive beliefs concern the
dangerousness and significance of intrusive thoughts/feelings. For
example, BDD patients may have so-called ‘positive’ metacognitive
beliefs about the consequences of their body ruminations. They
believe that these thoughts lead them to pay much more attention
to their appearance and, as a consequence, provide a condition
where other people see them as less ugly and which reduces the
others’ negative beliefs about them. Continuing body rumination,
however, causes negative metacognitive beliefs about these
persevered negative feelings and thoughts to increase and, even-
tually, the patient perceives them as dangerous and uncontrollable
events. This situation makes them more anxious and irritable.
Cooper and Osman (2007) suggested that patients with BDD do
indeed engage in metacognitive processing in relation to their
concerns with appearance. They report attempts to control, correct,
appraise, and regulate their thinking in relation to images and also
in relation to thoughts associated with their illness-related
concerns. Thus, as suggested by Veale (2004), metacognition may
be an important feature of information processing in BDD and may
be one way in which the symptoms of the disorder are maintained.
Theoretically, therefore, it may be an important dimension to beincorporated into a cognitive model of BDD. Further research is
needed into the phenomenon of metacognition, including its
characteristics, functions, and role in the maintenance of the dis-
tressing symptoms of BDD. Imagery has been accorded a particu-
larly important role in the maintenance of BDD, where mental
images of the self are thought to be a particularly central feature of
a cognitive conceptualization (Veale, 2004, 1996).
Metacognitive therapy has been pilot tested for OCD in a case
series (Fisher & Wells, 2008) and as a component of small group
treatment (Rees & Van Koesveld, 2008). According to some larger
studies it seems that metacognitive therapy is an effective inter-
vention for OCD (Fisher, 2009; Wells, 2000; Fisher &Wells, 2005b).
Following the S_REF model the cognitive attentional syndrome
(CAS) is a feature of many disorders. There is clear evidence of CAS
in BDD (e.g. worry & rumination, threat monitoring, mirror gazing
and mirror checking, and coping behaviors that backfire). Thus,
a treatment that would decrease CAS andmetacognition associated
with it should be effective for BDD. The present study investigated
the effects of metacognitive therapy on BDD symptoms, as BDD is
considered an OCD-spectrum disorder. As a manipulation check,
the effect on thought-fusion manifestations was also investigated.
2. Method
2.1. Participants
Patients were drawn from (n ¼ 100) consecutive referrals made
by general practitioners and psychiatrists to dermatologist and
cosmetic surgery clinics in the city of Isfahan, Iran. BDD diagnosis
was established using the structured clinical interview for DSM-IV
diagnoses (SCID, based on the Diagnostic and Statistical Manual of
Mental Disorderse 4th Edition, Text Revision (DSM-IV-TR; American
Psychiatric Association, 2000). The diagnoses were made by the
first author, holding a master’s degree in clinical psychology.
Thirty-one individuals met the criteria for diagnosis of BDD set by
DSM-IV-TR, of which 20 individuals were willing to participate in
our treatment study; their major problem was BDD. See Fig. 1 for
a flow chart.
Twenty patients were, thus, recruited (18 females), ages ranging
from 16 to 37 years (mean¼ 25.2; SD¼ 6.5). Seventeen (85%) of the
participants were single and 3 were married. Their socio-economic
status was average or above average. Classification of socio-
economic status was based on coding of the subjects’ income,
education and job. Also, they all had some high school diploma and
university education. None of the patients were currently taking
psychotropic medication (4 patients had previously taken clo-
mipramine and another one fluvoxamine, buspirone and lithium
carbonate). The duration of their BDD ranged from 1 to 10 years.
Fifty-five percent of the patients had a single diagnosis of BDD, and
45 percent had an additional diagnosis. Two patients met the
criteria for additional major depressive disorder. One patient met
the criteria for social phobia, and one patient had comorbid OCD.
The participants in the experimental group had one or more of the
following concerns: facial skin (n ¼ 3), hair (n ¼ 2), breasts (n ¼ 1),
eyes (n ¼ 1), and shape of the nose (n ¼ 3). The participants in the
control group had the following concerns: facial skin (n ¼ 4), hair
(n ¼ 2), breasts (n ¼ 1), eyes (n ¼ 1), and shape of nose (n ¼ 2).
Table 1 provides general characteristics of the study sample.
2.2. Design
The design of this study was experimental with pre-test,
post-test and follow-up. After completion of the baseline
assessment, patients who met the entry criteria and agreed to
participate in the study were randomly assigned to one of two
Table 1
Means (and SDs) of general characteristics of the patients (age, education, socio-
economic status, duration of past medication, ‘single concern’ versus ‘multiple
concerns’, comorbidity percentage and duration of BDD).
Experimental Control
Age 23.7 (6.5) 26.6 (6.6)
Education 2.1 (.73) 1.8 (.78)
High school diploma 20% 40%
Bachelor 50% 40%
Master 30% 20%




Past medication in years 1.3 (.67) 1.3 (.48)
Number of concerns 2.1 (1.4) 2.7 (1.8)
Percentage with comorbid diagnoses 40% 50%
Duration of BDD in years 11.1 (14.5) 11.2 (14.5)
Fig. 1. CONSORT 2010 Flow Diagram.
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author - was based on Simple Sampling to ensure balanced
group assignments. Participants were informed about the
assigned treatment only after the completion of the baseline
measurements. The experimental group (10 participants, 1 male)
received 8 sessions of 45e60 min of MCT while the control
group (10 participants, 1 male) remained in the waiting-list and
received no intervention. After the intervention, a postetest, and
after 6-months, a followeup measurement was taken. There was
one between subjects variable (Treatment: MCT vs Waiting) and
there was 1 within subjects variable (Time, with three levels:
pre, post and follow-up). The dependent variables were BDD
symptoms and thought-fusion symptoms in BDD.
2.3. Intervention
Patients received eight individual weekly sessions of meta-
cognitive therapy (MCT) of 45e60 min duration. Homework was
a component of treatment, and the metacognitive therapy was
carried out on the basis of Wells’ manual (2000). In order to
administer the Wells model to BDD, some modifications were
made.
The aim of MCT for BDD is to increase patients’ awareness of the
role thatmetacognitionplays inmaintaining their symptoms. Thegoal
is to enable patients to move from treating their thoughts about their
appearance as facts to objectively evaluate their appearance asmerely
mental events not requiring further processing. This is accomplished
by modifying metacognitive beliefs about appearance and rituals,reducing levels of rumination, worry, self-focused attention and
replacing maladaptive coping strategies with adaptive coping strate-
gies which facilitate the development of functional processing.
In the first session, an idiosyncratic case formulation based on
the metacognitive model of BDD was developed with each patient.
This was followed by socialization strategies in which the therapist
introduces the idea that a central problem is not the occurrence of
obsessional thoughts, doubts, feelings, but the meanings and
responses that are applied to them. The therapist emphasizes the
idea that it is the patient’s belief about these events and theway the
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fusion beliefs were then targeted using verbal reattribution and
within session behavioral experiments in which patients were
trained to respond to their preoccupation with ‘detached mindful-
ness’ (Wells, 2000; Wells & Mathews, 1994). Homework assign-
ments consisted of watching their obsessive thoughts about their
body as an observer and not to engagewith them in anyway. Due to
this practice, they were able to detach from internal thoughts and
feelings and to do this instead of ruminating, suppressing thoughts,
conducting behavioral rituals or behaviors in response to their
obsessional thoughts. Patients were asked to simply notice their
preoccupation and choose to let the thought decay naturally.
‘Detached mindfulness’ is achieved by giving the patient within
session practice of the strategy with emotionally neutral material
and is then practiced in response to their preoccupation. This
strategy aims to increase awareness of the maintaining role of
metacognitive beliefs in BDD, whilst at the same time modify both
metacognitive beliefs about appearance, as well as positive and
negative beliefs about rituals. Patients were then asked to imple-
ment the technique consistently between therapy sessions.
Subsequent treatment sessions involved further practice of
‘detached mindfulness’ and modification of beliefs about the
necessity of performing rituals in response to preoccupation
(positive metacognitive belief about rumination and worry).
Both positivemetacognitive beliefs about rituals (e.g., ‘my rituals
prevent me from looking terrible’) and negative metacognitive
beliefs about rituals (e.g., ‘my compulsions are uncontrollable and
will make me go mad’) were addressed in therapy. The next step in
treatment was to modify the maladaptive internal criteria that BDD
patients use to guide their overt and covert rituals. Patients usually
will continue to perform their rituals until an internal goal state is
achieved and use a range of maladaptive strategies in trying to
determine whether a situation is safe or dangerous. Attentional
strategies, such as hypervigilance, are often used for both internal
and external threat cues. Patients frequently display elevated
cognitive self-consciousness and engage in the monitoring of
mental events for absence/presence of intrusive thoughts.
Following advantagesedisadvantages analysis of these behaviors,
patients were asked to ban their maladaptive attentional strategies
and instead were reminded to use feelings of anxiety or inappro-
priatemonitoring as a cue to implement detachedmindfulness. The
final two treatment sessions focused on relapse prevention and
further modification of positive and negative metacognitive beliefs
which included erroneous beliefs about the recurrence of emotion
and deviations in mood. Relapse prevention involved the develop-
ment of a therapy blueprint which includes a written and dia-
grammatic formulation of the metacognitive model of BDD. A
detailed account of the main therapeutic strategies used during
treatment was also provided, along with a specific plan for the
patient to implement in guiding their thinking and behavioral style
in responses to future negative moods. Patients were encouraged to
implement these strategies to maintain and strengthen the gains
made over the course of treatment. For further details on the
treatment delivered in this study, see Wells (1997; 2000).
After the follow-up, the control group also received 5 sessions of
MCT, for ethical reasons. The content of these sessions was
comparable to the content of the experimental sessions but due to
financial and time limitations, the number of sessions was less (5
instead of 8), whereas the duration of the sessions was longer
(60e70 min instead of 45e60 min).
2.4. Treatment integrity
Treatment rationale, treatment model, treatment formulations,
therapeutic strategies and treatment targets were according to theMCT manual adapted for BDD patients and the therapist was
obliged to conduct the treatment precisely according to the MCT
manual adapted for BDD patients. The intervention was conducted
by one master’s degree clinical psychologist who had passed a 6-
month training of MCT. At the end of the sessions the first author
and the therapist discussed the contents of the sessions, to ensure
those sessions were based on MCT.
2.5. Measurements
The following measures were completed at the beginning and
end of the intervention (that is, 2-months after the start), and at 6-
months follow-up.
2.5.1. Yale-Brown Obsessive Compulsive Scale Modified for Body
Dysmorphic Disorder (BDD-YBOCS; Phillips & Hollander et al., 1997)
This is a reliable and valid 12-item semi-structured clinician
administered instrument that evaluates current BDD severity. It
assesses BDD-related preoccupations, repetitive behaviors, insight,
and avoidance (Phillips, 2009). The reliability and validity of the
BDD-YBOCS Farsi translated version was demonstrated by Rabiei,
Khormdel, Kalantari, and Molavi (2010) in both healthy and clin-
ical samples. They showed that alpha coefficients ranged from .78
to .93 for the BDD-YBOCS total score and for its subscales (preoc-
cupations, repetitive behaviors).
2.5.2. Thought Fusion Instrument (TFI; Wells et al., 2001)
This is a 14-item self-report scale that assesses metacognitive
beliefs about the meaning, significance and dangerousness of
intrusive thoughts. It consists of items tapping TAF, TEF and TOF.
Each item is rated on a 0-100 scale (where ‘0’ represents ‘I do not
believe this at all’, and ‘100’ represents ‘I am completely convinced
that this thought is true’). There are limited psychometric data
available, but Gwilliam, Wells, and Cartwright-Hatton (2004) ob-
tained excellent reliability (Cronbach’s alpha is .89). The scale
appears to have a single factor structure combining all items, and
preliminary evidence supports its convergent and discriminate
validity (Gwilliam, 2001). Moreover, Khormdel, Rabiei, and Molavi
(2010) showed that the TFI Farsi translated version in both healthy
and clinical samples had proper reliability and validity.
Patients’ satisfaction with treatment, therapist, content of
sessions, strategies taught, outcome and goals achieved were
assessed at post-treatment on a 6-point scale (1e6 where ‘1’
indicates minimum satisfaction and ‘6’ indicates maximum
satisfaction).2.6. Data reduction and analysis
First, we conducted descriptive statistics, including distribution
of continuous variables. We then calculated patients’ satisfaction
with treatment. Two repeated measures analyses of variance
(ANOVAs) were conducted to examine the effectiveness of meta-
cognitive therapy (MCT) on symptoms of BDD and thought-fusion
symptoms in BDD, respectively. Effect sizes were computed by
using Cohen’s d. Finally, clinically significant change percentages
were calculated for each group using a cut-off score of 20 on the
BDD-YBOCS.
3. Results
The results of Chi Square tests and ManneWhitney U-test
showed that the differences between the two groups were not
significant with regard to gender, education, socio-economic status,
and percentage suffering from comorbid diagnoses (p > .05).
Table 2
Means (and SDs) for BDD symptoms and Thought-Fusion at pre -treatment, post-
treatment, and follow-up in the experimental and the control group.
Experimental (N ¼ 10) Control (N ¼ 10)
Pre Post Follow-up Pre Post Follow-up
BDD-YBOCS 30.1 (6.5) 20.1 (6.9) 20.8 (5.85) 30.8 (8.4) 31.2 (8.6) 30.8 (8.5)
TFI 697 (1.6) 406 (1.7) 375 (9.55) 631 (1.99) 688 (1.5) 680 (1.2)
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the differences between the two groups were not significant with
regard to age, duration of past medication, number of concerns, and
duration of BDD (p > .05).
3.1. Treatment refusers and drop-outs
There were no drop-outs in this study. The mean number of
sessions that participants attended towas 6; Two participants were
absent for 2 sessions because of their final exams. We believe that
the reasons for the absence of drop-outs are as follows:
1- The participants were all highly motivated, well-educated and
volunteers
2- There was no charge for participation3.2. Patients’ satisfaction
The scores on patient’s satisfaction with treatment, therapist,
content of sessions, strategies taught, outcome and goals achieved,
assessed at post-treatment on a 6-point scale, ranged from 4.0 to
6.0 (mean ¼ 4.85, SD ¼ .93). This indicates that satisfaction of the
patients about the treatment was moderate to high.
3.2.1. Effects of treatment on BDD and TFI symptoms
The means of both dependent variables and standard deviations
of pre-test, post-test, and follow-up tests are presented in Table 2.
The assumption of normality was not rejected by the Shapir-
oeWilk test. Also the equality of population variances was not
rejected by Levene’s test.
The two groups did not differ significantly at pre-test with
regard to BDD and TFI symptoms (t (18) ¼ .21, p > .0.05 and
t(18) ¼ .81, p > .05, for both measurements, respectively).
The 2 (Group: treatment vs waiting)  3 (Time: pre vs post vs
follow-up) repeated measures ANOVA with BDD symptoms as the
outcome variable revealed a significant main effect of Time (F (2,
17)¼ 8.5; p< .005) and a significant interaction effect of Group and
Time (F(2, 17) ¼ 11.7; p < .005). Inspection of the means indicates
that individuals in the treatment group improved on BDD symp-
toms whereas control individuals remained stable across all time
points. The largest improvement on BDD scores was observed
between pre-test and post-test; an independent samples t-test
with BDD change score (post-test minus pre-test) as the dependent
variablewas significant (t(18)¼4.3, p< .001; mean change scores
being 10 and .4 for the experimental and control group, respec-
tively). Between post-test and follow-up, the scores of both groups
remained stable; that is, changes scores from post-test to follow-up
were not significantly different for both groups (t(18) ¼ 1.1 p > .05;
mean change scores being .7 and .4 for the experimental and
control group, respectively), indicating that the experimental
group’s improvement persisted at follow-up whereas the control
groups’ relatively unchanged higher scores persisted.
The 2 (Group: treatment vs waiting)  3 (Time: pre vs post vs
follow-up) repeated measures ANOVA with TFI symptoms as the
outcome variable revealed a similar pattern: there was a significantmain effect of Time (F (2, 17) ¼ 6.9; p < .01) and a significant
interaction effect of Group and Time (F(2, 17) ¼ 13.8; p < .001).
Inspection of the means indicates that individuals in the treatment
group improved on TFI symptoms whereas control individuals
remained stable. Here also, the largest improvement on TFI scores
was observed between pre-test and post test; a t-test with TFI
change score (post-test minus pre-test) as the dependent variable
was significant (t(18) ¼ 5.2, p < .001; mean change score being
291 and 57 for the experimental and control group, respectively).
Between post-test and follow-up, the scores of both groups
remained stable; that is, changes scores from post-test to follow-up
were not significantly different for both group (t(18) ¼ .5 p > .05,
mean changes scores being 30 and 8, for the experimental and
control group, respectively), indicating that the experimental
group’s TFI score improvement persisted at follow-up whereas the
control groups’ unchanged higher TFI scores remained.
The effect size of MCT in this study as compared to the waiting-
list group was Cohen’s d ¼ .33 for BDD symptoms and Cohen’s
d ¼ .51 for TF. At post-test, 70 percent of the patients in the
experimental group had a clinically significant recovery score (20
or below) on the BDD-YBOCS versus none of the patients in the
wait-list control group. At follow-up, these percentages were 60
versus 0 in the experimental and the control group, respectively.
Overall, the analyses showed that MCT had a significant effect
on reducing the symptoms of BDD and TFI in BDD patients
compared with the control group.
4. Discussion
Despite recent advances in developing effective treatments for
Body Dysmorphic Disorder, much less treatment outcome research
has been carried out on BDD than on any other serious mental
disorder, and more treatment research is urgently needed. The
present study aimed to further explore treatment possibilities for
BDD with regard to metacognitive components, as Cooper and
Osman (2007) have shown that there metacognitions and BDD
symptoms are related.
MCT deals with the way patients with BDD think and it assumes
that the problem rests with inflexible and recurrent styles of
thinking in response to negative thoughts, feelings and beliefs. In
this study, the patients were taught that metacognitive beliefs e
such as the belief that worry or rumination is an effective desirable
coping strategy - are an important factor contributing to the
maintenance of BDD. However, metacognitive beliefs do not
provide information that disconfirms negative beliefs or appraisals.
This is the first study to evaluate the effects of MCT on Thought-
Fusion symptoms in BDD. The results showed that this form of
treatment was associated with reductions in Thought-Fusion
symptoms in BDD. The post-treatment effect sizes for MCT were
very large and support the continued evaluation of MCT in severe
and enduring mental health problems.
Patients appeared to tolerate the treatment well and were able
to comply with their homework. This is congruent with the MCT
theory of Wells (Fisher, 2009; Fisher & Wells, 2008; Wells, 2000,
2009; Wells & Matthews, 1994) and studies about the efficacy of
MCT on emotional disorders (e.g. ObsessiveeCompulsive Disorder,
Generalized Anxiety Disorder and Post Traumatic Stress Disorder).
The effect size of MCT in this study as compared to the waiting-
list group was Cohen’s d ¼ .33 for BDD symptoms and Cohen’s
d ¼ .51 for TF. In comparison, Rosen et al. (1995) reported an 82%
response rate in BDD patients randomized to a CBT group treat-
ment. Also, in ameta-analysis done byWilliams, Hadjistavropoulos,
and Sharpe (2006), both medication and CBT were shown to be
effective in treating BDD, although CBT was associated with
significantly higher effect sizes than medication (d ¼ 1.78 and
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approach for BDD. Future research, studying the effects of CBT
directly against those of MCT and medication in bigger patient
samples, may show which of these therapies would be more
effective in BDD patients.
There are also limitations in this study, meaning that the results
need to be interpreted with some caution. First, MCT is a relatively
new technique, which has not yet been investigated extensively in
OCD, only by means of case studies. The effects should be inter-
preted with a little caution, as they might partly be explained by
treatment novelty. Next, because of the small sample size, it was
not possible to compare MCT to another form of treatment to
control for the effect of therapist attention. Furthermore, although
MCT was manual-based and efforts have been made to ensure that
the intervention was according to MCT only (and not other thera-
pies), it would be better if treatment sessions were recorded and
checked by independent raters. As the participants in this project
were volunteers, highly educated, young and mostly female and
single, generalization of the findings should be done only with
caution. Another limitation of the study may go back to the
inequality of the participants in both groups concerning gender.
Next, the first author was aware of the participant’s group
membership. Furthermore, delusional patients could not be
distinguished from non-delusional patients, as we did not assess
delusionality. Since our patients were all in the mild-moderate
YBOCS scores range, and had relative lack of general comorbidity,
we believe that they were not delusional, and perhaps are more
cognitively flexible. Next, the items of TOF, TEF, and TAF scales e
originally designed for OCD- were not adapted for specific assess-
ment of BDD (and thoughts about appearance). Although we feel
that there are a lot of similarities between OCD and BDD, the results
should be cautiously generalized to a BDD population. Finally, there
were no other self-report BDD symptom or quality of life scales
which limits the results. In future studies it is recommended that
the effects of MCT, CBT and medication therapy be directly
compared. Moreover, it is suggested that non volunteer partici-
pants, lower educated and other age ranges, and particularly male
and married participants, with larger sample sizes.
All in all, it can be concluded that MCT is an effective treatment
for BDD. Furthermore, the effect was somewhat more pronounced
in Thought-Fusion symptoms than in BDD symptoms. This paper
aimed to describe the aspects of the metacognitive model and
treatment of BDD. It is possible that an explicit treatment focus on
metacognition could improve the absolute efficacy rates for this
disorder. Whilst studies evaluating the efficacy of metacognitive
therapy are in their infancy, the results thus far are promising and
merit further large scale investigations. A fascinating and enlight-
ening study would be a direct comparison of MCT with CT, CBT and
drug therapy. This would further highlight the differences and
similarities between treatment approaches and their putative
mechanisms of action in BDD.
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